UNICHEMLABNSEUnichem Laboratories Limited· PharmaceuticalsHighPositive
Announced Fri, 22 May · 16:44 IST

Unichem Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.

Management Changes View source PDF

UNICHEMLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-4.7%1-day move
₹372.60
prior close
₹361.05
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.4-0.9-1.0-0.8-4.7-5.2-6.1-8.9-1.8-0.9+19.8+16.1+45.0
Up moveDown movePending
AI summary

Unichem Laboratories reported FY26 consolidated revenue of Rs 2,201.85 crore, up 4.3% from Rs 2,110.97 crore in FY25. Net profit after tax (consolidated) rose to Rs 252.84 crore from Rs 137.52 crore, boosted by a Rs 275.52 crore gain on sale of the erstwhile registered office and reversal of EU fine provisions, partly offset by a Rs 201.86 crore net exceptional charge (including Rs 58.26 crore EU interest and Rs 15.40 crore new labour code impact). The Board redesignated Mr. Pabitrakumar Bhattacharyya as Managing Director & CEO and re-appointed him for three years from August 2026 (subject to shareholder approval). Auditors gave an unmodified opinion. Both cost and internal auditors were reappointed for FY27.

Likely market impact

Strong bottom-line growth driven by asset sale gains masks weaker underlying operations; the CEO consolidation and extension provides leadership stability ahead of the new term. Q4 standalone loss of Rs 15.39 crore warrants attention on standalone performance.